Pieris Pharmaceuticals Gmbh

Pieris Ag

Pieris Pharmaceutical Gmbh

Hendrik Gille

Laurent Audoly

Andrea Allersdorfer

Andreas Hohlbaum

Rachida Siham Bel Aiba

Shane Olwill

Stefan Trentmann

Christine Rothe

Alexander Wiedenmann

Arne Skerra

Marlon Hinner

Gabriele Matschiner

Kristian Hobolt Jensen

Martin Huelsmeyer

Hans-Juergen Christian

Elisabeth De Vries

Anton G T Terwisscha Van Scheltinga

Andrea Allensdorfer

Kathleen Marie Campbell

Anton Gt Terwisscha Van Scheltinga

Anton GT Terwisscha Van Scheltinga

Sankaram Bhima Mantripragada

The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)

Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof

The present disclosure relates to a method of treating, ameliorating or preventing a disorder by blocking the signaling pathway of c-Met, wherein said method comprises the step of administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof. In addition, the present disclosure relates to a diagnostic composition suitable for use in, e.g., an immuno-imaging technique to detect the presence of c-Met as well as the uses thereof.

Methods and compositions for treating disorders

The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof capable of increasing the bioavailability of iron in the subject.

Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation

The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.

Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins that bind hepcidin and nucleic acid encoding such

Growing community of inventors

Munich, Germany

Hendrik Gille